Skip to main content
SpringerLink
Log in
Book cover

Clinical Reproductive Medicine and Surgery pp 259–268Cite as

Ovarian Reserve Testing

  • Chapter
  • First Online:

  • 1278 Accesses

Abstract

The general purpose of ovarian reserve testing is to assess the quantity and quality of the remaining oocytes in an attempt to predict reproductive potential. Ovarian reserve testing should be performed in women older than 35 years who have not conceived after 6 months of attempting pregnancy (or women less than 35 who have not conceived after 1 year) and women at higher risk of diminished ovarian reserve, such as those with a history of cancer or other medical condition treated with gonadotoxic therapy and/or pelvic irradiation, or women who have had ovarian surgery for endometriomas.

Available tests for ovarian reserve include biochemical markers, i.e., FSH, estradiol, AMH, and inhibin B and ovarian ultrasound imaging, i.e., antral follicle count and ovarian volume. For general obstetrician-gynecologists, the most appropriate ovarian reserve screening tests to use in practice are basal FSH plus estradiol levels or anti-Müllerian hormone (AMH) levels. An antral follicle count (AFC) may also be useful if there is an indication to perform transvaginal ultrasonography. These screening tests are better predictors of oocyte yield from ovarian stimulation during in vitro fertilization (IVF) than rate of pregnancy. Low ovarian response to stimulation, usually defined as fewer than three to five developing follicles during an IVF cycle, is an indicator of a poor reproductive outcome. It is important to recognize, however, that a poor result from ovarian reserve testing does not signify an absolute inability to conceive and should not be the sole criteria considered to limit or deny access to infertility treatment. Although these tests are used to assess oocyte quantity and quality, the best surrogate marker for oocyte quality is age. At this time, ovarian reserve testing results cannot be extrapolated to predict the likelihood of spontaneous conception.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

Ovarian reserve:

A description of the quantity and quality of the oocytes left in the ovary

Anti-Müllerian hormone:

A glycopeptide that is produced predominantly by granulosa cells whose expression is highest in secondary, preantral, and small antral follicles

Antral follicle count:

An ultrasound observation of the number of visible ovarian follicles (2–10 mm mean diameter) in the early follicular phase (cycle days 2–5)

References

  1. Committee on Gynecologic Practice. Committee opinion no. 618: ovarian reserve testing. Obstet Gynecol. 2015; 125(1): 268–73.

    Google Scholar 

  2. Faddy MJ, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342–6.

    Article  CAS  PubMed  Google Scholar 

  3. Gnoth C, et al. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod. 2003;18(9):1959–66.

    Article  CAS  PubMed  Google Scholar 

  4. Centers for Disease Control and Prevention, A.S.f.R.M., Society for Assisted Reproductive Technology. Assisted reproducrtive technology fertility clinic success rates report. Atlanta: Department of Health and Human Services; 2010. p. 2014.

    Google Scholar 

  5. Brodin T, et al. Menstrual cycle length is an age-independent marker of female fertility: results from 6271 treatment cycles of in vitro fertilization. Fertil Steril. 2008;90(5):1656–61.

    Article  PubMed  Google Scholar 

  6. Esposito MA, Coutifaris C, Barnhart KT. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum Reprod. 2002;17(1):118–23.

    Article  CAS  PubMed  Google Scholar 

  7. Roberts JE, et al. Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization. Fertil Steril. 2005;83(1):37–41.

    Article  PubMed  Google Scholar 

  8. Abdalla H, Thum MY. Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH. Hum Reprod. 2006;21(1):171–4.

    Article  CAS  PubMed  Google Scholar 

  9. Broekmans FJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685–718.

    Article  CAS  PubMed  Google Scholar 

  10. Sowers MR, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tsepelidis S, et al. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22(7):1837–40.

    Article  CAS  PubMed  Google Scholar 

  12. Bentzen JG, et al. Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. Hum Reprod. 2013;28(1):247–55.

    Article  CAS  PubMed  Google Scholar 

  13. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod. 2007;22(9):2414–21.

    Article  CAS  PubMed  Google Scholar 

  14. Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimullerian hormone. Fertil Steril. 2013;99(7):1825–30.

    Article  CAS  PubMed  Google Scholar 

  15. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9–e17.

    Article  Google Scholar 

  16. McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod. 2007;22(3):778–85.

    Article  CAS  PubMed  Google Scholar 

  17. Muttukrishna S, et al. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG. 2004;111(11):1248–53.

    Article  CAS  PubMed  Google Scholar 

  18. Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014;12:26.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99(4):963–9.

    Article  CAS  PubMed  Google Scholar 

  20. Broer SL, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26–36.

    Article  PubMed  Google Scholar 

  21. La Marca A, et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online. 2011;22(4):341–9.

    Article  CAS  PubMed  Google Scholar 

  22. Lee TH, et al. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol. 2009;7:100.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lukaszuk K, et al. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization. Eur J Obstet Gynecol Reprod Biol. 2013;168(2):173–7.

    Article  PubMed  Google Scholar 

  24. Brodin T, et al. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab. 2013;98(3):1107–14.

    Article  CAS  PubMed  Google Scholar 

  25. Dolleman M, et al. The relationship between anti-Mullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. J Clin Endocrinol Metab. 2013;98(5):1946–53.

    Article  CAS  PubMed  Google Scholar 

  26. Kwee J, et al. Intercycle variability of ovarian reserve tests: results of a prospective randomized study. Hum Reprod. 2004;19(3):590–5.

    Article  CAS  PubMed  Google Scholar 

  27. Hendriks DJ, et al. The clomiphene citrate challenge test for the prediction of poor ovarian response and nonpregnancy in patients undergoing in vitro fertilization: a systematic review. Fertil Steril. 2006;86(4):807–18.

    Article  CAS  PubMed  Google Scholar 

  28. Hendriks DJ, et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005;83(2):291–301.

    Article  PubMed  Google Scholar 

  29. Jayaprakasan K, et al. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010;93(3):855–64.

    Article  CAS  PubMed  Google Scholar 

  30. Steiner AZ. Biomarkers of ovarian reserve as predictors of reproductive potential. Semin Reprod Med. 2013;31(6):437–42.

    Article  PubMed  Google Scholar 

  31. Scott Jr RT, et al. Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril. 1990;54(2):297–302.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Oregon Health and Science University, 3303 SW Bond Ave, CH10F, Portland, OR, 97239, USA

    Paula Amato MD, MCR

Authors
  1. Paula Amato MD, MCR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paula Amato MD, MCR .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio, USA

    Tommaso Falcone

  2. Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA

    William W. Hurd

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Amato, P. (2017). Ovarian Reserve Testing. In: Falcone, T., Hurd, W. (eds) Clinical Reproductive Medicine and Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-52210-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52210-4_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52209-8

  • Online ISBN: 978-3-319-52210-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation